



Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies

Benoit Llopis, Alexandre Bleibtreu, Dimitri Schlemmer, Pascal Robidou, Olivier Paccoud, Nadine Tissot, Gaëlle Noé, Helga Junot, Charles-Édouard Luyt, Christian Funck-Brentano, et al.

► To cite this version:

Benoit Llopis, Alexandre Bleibtreu, Dimitri Schlemmer, Pascal Robidou, Olivier Paccoud, et al.. Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies. *Clinical Chemistry and Laboratory Medicine*, 2021, 10.1515/cclm-2021-0423 . hal-03283960

HAL Id: hal-03283960

<https://hal.sorbonne-universite.fr/hal-03283960>

Submitted on 12 Jul 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies.

Benoit Llopis ^{1,2}, Alexandre Bleibtreu ³, Dimitri Schlemmer ², Pascal Robidou ¹, Olivier Paccoud ³, Nadine Tissot ^{1,2}, Gaëlle Noé ^{1,2}, Helga Junot ⁴, Charles-Édouard Luyt ⁵, Christian Funck-Brentano ¹, Noël Zahr ^{1,2}.

1. AP-HP. Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1901, Pharmacokinetics and Therapeutic Drug Monitoring Unit, UMR-S 1166, F-75013 Paris, France.

2. AP-HP. Sorbonne Université, Laboratoire de suivi thérapeutique pharmacologique spécialisé, F-75013 Paris, France.

3. AP-HP. Sorbonne Université, Pitié-Salpêtrière Hospital, Service de Maladies Infectieuses et Tropicales, Paris, France.

4. AP-HP. Sorbonne Université Pharmacy Department, Pitié-Salpêtrière Hospital, 75013 Paris, France.

5. AP-HP. Sorbonne Université, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France

Corresponding Author :

Dr Noël Zahr,
Service de Pharmacologie
Hôpital Pitié-Salpêtrière, APHP, 75013 Paris, France
Tel: + 33 1 42 16 20 15, Fax: +33 1 42 16 20 46
Email: noel.zahr@aphp.fr

Running title: Cefiderocol and ceftobiprole quantification by LC-MS/MS

Target journal: Clinical Chemistry and Laboratory Medicine

Abstract: 239/250 words

Total text: 3526/3500 words

Figures and Tables: 7/8

References: 33/50

Keywords: 6/6

Abstract

Objectives: Cefiderocol and ceftobiprole are new generation cephalosporin antibiotics that exhibit high inter-individual plasma concentration variability that potentially impact their efficacy or toxicity. The aim of this study was to develop and validate a selective, simple and fast UPLC-MS/MS method for simultaneous quantification of cefiderocol and ceftobiprole in human plasma to enable their therapeutic drug monitoring and support PK and PK/PD studies, in particular in critically ill patients.

Methods: After a simple and fast single-step protein precipitation, cefiderocol and ceftobiprole were separated on a Waters Acquity UPLC BEH C18 column by linear gradient elution; with subsequent detection by Shimadzu MS 8060 triple quadrupole tandem mass spectrometer in a positive ionization mode.

Results: Analysis time was 5 minutes per run. The analytical performance of the method in terms of specificity, sensitivity, linearity, precision, accuracy, matrix effect, extraction recovery, limit of quantification, dilution integrity and stability of analytes under different conditions met all criteria for a bioanalytical method for the quantification of drugs. The calibration curves were linear over the range of 1-200 mg/L for cefiderocol and 0.5-100 mg/L for ceftobiprole with a linear regression coefficient above 0.995 for both.

Conclusion: A simple, fast, and selective liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous quantification of cefiderocol and ceftobiprole. This new method was successfully applied to the measurement of plasma concentration of cefiderocol and ceftobiprole in critically ill patients and showed good performance for their therapeutic monitoring and optimizing antibiotic therapy.

Keywords: liquid chromatography, mass spectrometry, cefiderocol, ceftobiprole, cephalosporin, therapeutic drug monitoring.

1. Introduction

Ceftobiprole, a fifth-generation parenteral cephalosporin, has shown antimicrobial activity against a large range of bacteria involved in pneumonia, including Gram-positive bacteria (GPB), such as methicillin-resistant *Staphylococcus aureus* (MRSA), *Enterococcus faecalis*, and *Streptococcus pneumoniae*, and Gram-negative bacteria (GNB), such as *Pseudomonas aeruginosa* and *Haemophilus influenza* [1]. Hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP) are among the most common infections treated in the hospital setting [2, 3]. Two randomized, double-blind, phase III clinical trials have demonstrated the efficacy of ceftobiprole in patients with HAP or CAP [4, 5]. Ceftobiprole exhibits high inter-individual pharmacokinetic (PK) variability [6]. Moreover, an exposure-efficacy relationship [7] and an exposure-toxicity relationship [8] have been demonstrated. The PK variability and the pharmacokinetics/pharmacodynamics (PK/PD) relationship of ceftobiprole suggest the potential interest of its routine therapeutic drug monitoring (TDM).

Cefiderocol (S-649266) is a newly Food and drug administration (FDA) and European Medicines Agency (EMA) approved, first in its class, parenterally administered siderophore cephalosporin with a novel mechanism to penetrate the outer cell membrane of GNB, including multidrug-resistant strains [9]. The emergence of carbapenem resistance in many GNB, involved in a variety of serious infections including pneumonia, urinary tract infections, intra-abdominal infections and bloodstream infections, is an urgent threat to global public health [10-13], and the presence of multi-drug resistance complicates the management of these infections due to the limited treatment options available [14, 15]. Data from global surveillance studies for cefiderocol have shown potent *in vitro* activity against a wide range of GNB, including carbapenem-resistant *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, Enterobacteriaceae and *Stenotrophomonas maltophilia* strains [16]. The noninferiority and tolerability of cefiderocol versus imipenem-cilastatin was demonstrated in a randomized,

double blind, phase II study for the treatment of patients with complicated urinary tract infections due to multidrug-resistant GNB [17]. The PK profile of cefiderocol has been described in phase I and II single- and multiple-dose clinical studies [18-20]. PK and safety have also been described in subjects with renal impairment [19, 20]. However, the population PK and PK/PD properties of cefiderocol in ill patients, and specifically in critically ill patients are currently limited [21]. This is particularly important because there are, in this population, several co-morbidities and modifications of the physiological state which can modify the PK and PK/PD profiles of most beta-lactam antibiotics used in clinical practice [22-26]. The aim of this study was to develop and validate a selective, simple and fast UPLC-MS/MS method for simultaneous quantification of cefiderocol and ceftobiprole in human plasma to enable their TDM and support PK and PK/PD studies.

2. Materials and methods

2.1. Chemical and reagents

Cefiderocol and [2H₁₂]-cefiderocol powders were provided by Shionogi & Co, Ltd (Osaka, Japan) while ceftobiprole (BAL9141, the active form) and [2H₄]-ceftobiprole powders were provided by Basilea Pharmaceutica Ltd (Basel, Switzerland). The chemical structures and mass spectrum of cefiderocol and ceftobiprole are shown in **Figure 1** (mass spectrum of [2H₁₂]-cefiderocol and [2H₄]-ceftobiprole are shown in **Supplemental Figure 1**). Methanol was obtained from Merck (Darmstadt, Germany). Formic acid and ammonium acetate were obtained from Sigma-Aldrich (Munich, Germany). Sulphosalicylic acid dihydrate (SSA) and acetonitrile were obtained from VWR (Fontenay-sous-Bois, France). All reagents used were of the highest available analytical grades. Liquid chromatography–MS/MS grade water (ultra-pure water) was purchased from a water distribution hypergrade system Purelab Flex®

(ELGA®), and drug-free plasma from healthy donors was supplied by the French Blood Establishment (Paris, France).

2.2. Preparation of stock solutions, standards and quality control samples

Individual stock solutions of cefiderocol and ceftobiprole were prepared at 1,000 mg/L. Cefiderocol was prepared in ultra-pure water while ceftobiprole was prepared in a solution of methanol-hydrochloric acid 1N (95:5, v/v). Working solutions of cefiderocol and ceftobiprole, obtained by diluting the stock solution with methanol, were used to spike drug-free plasma to prepare independent calibration standards and quality control (QC) samples. Calibration ranges covered in the current method are: 1-200 mg/L (1-5-10-25-50-100-200) for cefiderocol and 0.5-100 mg/L (0.5-1-5-10-25-50-100) for ceftobiprole. The QC samples were tested at four different concentrations: high QC (HQC: 80% of upper limit of quantification [ULOQ]), medium QC (MQC: 50% of selected range), low QC (LQC: 2 times the lower limit of quantification [LLOQ]) and QC at LLOQ. A solution of mix (ISmix) of [2H₁₂]-cefiderocol and [2H₄]-ceftobiprole, used as internal standard, at 10 mg/L for both, was prepared in ultra-pure water. Stock solutions, working solutions, calibration standards, ISmix and QC samples were stored at -80°C.

2.3. Instruments and analytical conditions

Chromatography was performed on a Nexera X2 system (Shimadzu, Japan) with an autosampler temperature at 8°C. Acquity UPLC BEH C18 column (4.6 x 50 mm, 3.5 µm particle size) was used for chromatographic separation and column temperature was maintained at 45°C. Separation of cefiderocol and ceftobiprole was achieved over 5 min using two mobile phases: (A) water-formic acid (100:0.1, v/v)-ammonium acetate 2 mM and (B) acetonitrile-formic acid (100:0.1, v/v). A binary pump delivered the mobile phases at a flow rate of 0.5 mL/min using a linear gradient elution. The UPLC system was coupled to a triple

quadripole mass spectrometer: MS 8060 (Shimadzu, Japan). Quantifications were achieved in Multiple Reactions Monitoring (MRM) mode and electrospray ionization (ESI) was operated in positive mode. The interface temperature, the desolvation line (DL) temperature and the heat block temperature were set at 300°C, 250°C and 400°C, respectively, with a drying gas flow of 10.0 L/min and a nebulizing gas flow of 3.0 L/min. The interface voltage was set at 4.0 kV. Argon was used as collision gas. Chromatographic data acquisition; peak integration and quantification were performed using LabSolutions Insight LC-MS 3.2 SP1 software.

2.4. Samples pre-treatment

Sample preparation was performed by protein precipitation: 10 µL of 30% sulphosalicylic acid and 50 µL of ISmix were added to 100 µL of human plasma, calibrator or QC samples. The mixture was vortexed for 1 min and centrifuged for 10 min at 18,900 g at room temperature. Subsequently, 5 µL of the clear supernatant was transferred to an autosampler vial containing 200 µL of mobile phase A. 1 µL was injected into the LC-MS/MS system.

2.5. Method validation

The validation was performed according to *European Medicines Agency* (EMA) guideline for the validation of bioanalytical methods [27]. Parameters included were selectivity, carry-over, linearity, accuracy and precision, lower limit of quantification, matrix effect, stability in human plasma and dilution integrity.

2.5.1. Selectivity

The analytical method should be able to differentiate the analyte(s) of interest from endogenous components in the matrix or other components in the sample such as other drugs. To perform this, fifteen different sources of plasma samples were tested. A selective method should not have interference of more than 20% of the LLOQ for the analytes and 5% for the ISs.

2.5.2. Carry-over

Carry-over was assessed by injecting drug-free plasma samples after a high concentration calibrator. Carry-over in the drug-free plasma samples following the high concentration calibrator should not be greater than 20% of the LLOQ.

2.5.3. Linearity

Calibration curve was acquired by plotting the peak area ratio of the concentration of cefiderocol and ceftobiprole standards to the area of their respective isotopic IS over the range from 1 to 200 mg/L for cefiderocol and 0.5 to 100 mg/L for ceftobiprole. Curves were assayed by least square weighted (1/x). Linearity was defined by a linear regression coefficient $(R)^2 \geq 0.995$.

2.5.4. Precision and accuracy

The intra-day precision and accuracy were evaluated using six different replicates, extracted in the same day, at the four QC levels (LLOQ, LQC, MQC and HQC). The inter-day precision and accuracy were determined by repeating each QC levels six times a day for three consecutive days (n = 18 replicates). The concentration of each QC levels was determined using calibration standards prepared on the same day. The precision was calculated as the coefficient of variation (CV, %) within a single run (intra-day assay) and between different runs (inter-day assay), and the accuracy as the percentage ratio of the measured and nominal concentration $(\text{mean of measured/nominal} \times 100)$. The acceptance limits were CV <15% for precision and within $\pm 15\%$ of the nominal concentration for accuracy (ranged from 85-115%), except for the LLOQ at which deviation of 20% is acceptable.

2.5.5. Lower limit of quantification

The signal of the analyte at the LLOQ should be at least 5 times higher than that of a drug-free plasma sample. LLOQ should be measured with a variation not exceeding 20% of the nominal expected value and a CV <20%. The LLOQs of cefiderocol and ceftobiprole were selected as the lower concentration covered by the selected range.

2.5.6. Matrix effect and extraction recovery

Matrix effect (ME) and extraction recovery (ER) were assessed at two QC levels (LQC and HQC) in quintuplicate with five different sources of plasma. The approach involves determination of ratio of peak areas of analytes in three different sets [28]. One consisting of analyte standards in methanol (set A), one prepared in drug-free matrix extracts and spiked after extraction (set B), and one prepared in drug-free matrix from the same sources but spiked before extraction (set C). ME and ER were calculated by the following equations: ME (%) = $B/A \times 100$ and ER (%) = $C/B \times 100$. Normalized ME was obtained by dividing the values reported for the analytes by those of the IS. A value above or below 100% for the ME indicates an ionization enhancement or suppression respectively. The CV obtained for the IS-normalized ME should be less than 15%.

2.5.7. Stability

The stability in human plasma of cefiderocol and ceftobiprole in different storage conditions was performed at LQC, MQC and HQC. During each day tested, we used freshly prepared calibrators and each QC levels were analysed on three different replicates. The value was estimated by comparing measured concentration before storage to after storage, and reported as the percentage ratio of mean measured concentration to nominal concentration. The short term stability at room temperature (bench-top stability) was evaluated by measuring each QC level, stored at 25°C, every hour for 8 consecutive hours. The short term stability in the fridge was determined after 24h at 4-8°C and the short term stability in the freezer was determined

after 1 week at -25°C. The long term stability was determined after 2 month storage at -80°C. The freeze and thaw stability was estimated after three complete freeze and thaw cycles of -80°C to 25°C. Stability of extracts kept onboard the autosampler at 8°C during 24h was also tested. Cefiderocol and ceftobiprole was considered to be stable in plasma, during this different storage conditions, when measured concentration within $\pm 15\%$ of the nominal concentration.

2.5.8. Dilution integrity

The dilution integrity was examined to ascertain that an unknown sample with concentration exceeding the upper limit of compound calibration range, could be diluted with drug-free matrix without influencing the accuracy and precision of the measurement. To achieve this, a sample was prepared in a two-fold higher concentration than of the ULOQ (400 mg/L for cefiderocol and 200 mg/L for ceftobiprole) followed by dilution (1:3) in drug-free plasma before extraction. Diluted sample was tested for accuracy and precision: the acceptance limits were CV <15% for precision and within $\pm 15\%$ of the nominal concentration for accuracy. Samples were analyzed in quintuplicate.

2.6. Clinical application

This UPLC-MS/MS quantification method was applied to measurement of cefiderocol and ceftobiprole in plasma of critically ill patients hospitalized in ICU at Pitié-Salpêtrière hospital (Paris, France) to perform TDM and PK studies. Ten patients with compassionate use of cefiderocol and twenty five patients treated with ceftobiprole were included in the study. Cefiderocol and ceftobiprole were administrated by intravenous infusion over 3-hours and over 2-hours, respectively, and two successive blood samples were collected into lithium heparin tubes at steady state for both: one prior to the start of the infusion (C_{trough}) and one 15 ± 10 min after the end of the infusion (C_{max}). Plasma samples were prepared by centrifuging

collected blood samples for 5 min at 4,500 g at room temperature. All plasma samples were frozen at -80°C until analysis, and were process and analysed as previously described. French regulations on non-interventional observational studies do not require patient's consent when analyzing data obtained from routine care. Approval for data collection was obtained from the Commission Nationale de l'Informatique et des Libertés (n°1491960v0).

3. Results

3.1. Optimization of LC-MS/MS conditions

Electrospray positive mode yielded a better spectrometer response than the negative mode. To achieve symmetrical peak shapes, good resolution and a short chromatographic run time, a mobile phase consisting of (A) water-formic acid (100:0.1, v/v)-ammonium acetate 2 mM and (B) acetonitrile-formic acid (100:0.1, v/v) was used in the experiments using gradient elution: the gradient was initiated at 3% B, then increasing linearly to 51.3% B in 2 min, after which it was directly changed to 100% B, where it was maintained for 1 min, before returning to the initial condition for the last 2 min, resulting in a total run time of 5 min. Mass spectrometry parameters for the LC-MS/MS determination of cefiderocol, ceftobiprole and their respective IS are shown in **Table 1**.

3.2. Method validation

3.2.1. Selectivity and carry-over

Fifteen different sources of heparin-plasma samples without analytes but containing the following anti-infective drugs: levofloxacin, ciprofloxacin, moxifloxacin, rifampicin, ceftazidime, cefepime, amoxicillin, voriconazole, posaconazole, fluconazole and isavuconazole were tested. These anti-infective drugs were tested due to their relatively common use in ICU and for their possible concomitant administration in our cohort of patients. No interference with endogenous compounds or tested anti-infective drugs was

observed above 20% of the LLOQ of cefiderocol or ceftobiprole and above 5% of their respective IS. Furthermore, these same fifteen heparin-plasma samples were spiked at the LLOQ of cefiderocol and ceftobiprole and were tested for accuracy and precision. No significant interference was found in spiked plasma samples compared to non-spiked samples. The accuracy (% true) and precision (% CV) of the spiked samples were: cefiderocol (112; 10.7) and ceftobiprole (109; 11.2) indicating an absence of significant interference that could influence the accuracy and precision of the measurement.

The carry-over observed was less than 20% of the LLOQ for both drugs [cefiderocol (8.4%); ceftobiprole (1.8%)]. Furthermore, no carry over was observed for the IS used. The MRM-chromatogram of drug-free plasma sample of ceftobiprole and cefiderocol are shown in **Figure 2A4 and 2B4** respectively.

3.2.2. Linearity

Calibration curve were linear with linear regression coefficient $(R)^2 \geq 0.995$ for both analytes (0.998 and 0.999 for cefiderocol and ceftobiprole respectively). All calibrators, analyzed on seven different days, were measured with an accuracy ranged from 87-111% and coefficient of variation less than 10.2%. The highest calibration point was defined as ULOQ. The MRM-chromatogram of ceftobiprole and cefiderocol at their ULOQ are shown in **Figure 2A2 and 2B2** respectively. The linear regression equations of pooled data obtained over seven distinct days were: $y = 0.20360x - 0.08026$ and $y = 0.72831x - 0.07829$ for cefiderocol and ceftobiprole respectively.

3.2.3. Accuracy and precision

Intra- and inter-day precision and accuracy outcomes of QC samples are shown in **Table 2**. The intra- and inter-day coefficients of variation ranged from 2.6% to 5.3% and from 4.5% to 10.4% respectively, for both analyte at all tested concentrations (LQC, MQC and HQC).

Likewise, the intra- and inter-day accuracy ranged from 91-108% and from 92-102% respectively, for both analyte at all tested concentrations (LQC, MQC and HQC).

3.2.4. Lower limit of quantification

The LLOQ was established at 0.5 mg/L for **ceftobiprole** and at 1 mg/L for cefiderocol (**Table 2**). The MRM-chromatogram of **ceftobiprole** and cefiderocol at their LLOQ are shown in **Figure 2A1 and 2B1** respectively.

3.2.5. Matrix effect and extraction recovery

Table 3 presents the matrix effect (absolute and IS-normalized) and extraction recovery data at low and high concentrations **using heparin-plasma samples containing different anti-infective drugs (see list in selectivity section)**. For cefiderocol, a significant ion enhancement was observed, but this matrix effect was compensated by the use of its isotope-labeled IS. The CV of the IS-normalized matrix effect was less than 15% for both analyte. The absolute extraction recovery for both analyte ranged from 90 to 103%, with in all instances CVs below 10%.

3.2.6. Stability

Analyte stability was determined at five different storage conditions, using three concentrations of QC (LQC, MQC, HQC), as percent ratio of mean measured concentration to nominal concentration. Results are summarized in **Table 4**. The long term stability proved that both analytes are stable in plasma for at least 2 months at -80°C and after three cycles of freeze and thaw. The short term stability proved that both analytes are stable for 8h at room temperature; 24h at 4°C; **for at least** 1 week at -25°C and for 24h in the autosampler after extraction. **In addition, the stock, working and ISmix solutions have also been stable at -80°C for at least 2 months.**

3.2.7. Dilution integrity

The accuracy (% true) and precision (% CV) of the diluted sample were: cefiderocol (94; 5.7) and ceftobiprole (106; 7.2).

3.3. Clinical application

This validated UPLC-MS/MS method was successfully applied to the measurement of plasma concentration of cefiderocol and ceftobiprole in critically ill patients. For cefiderocol, the usual dosing was 2g TID [three times a day] (6/10). Three patients with renal impairment were treated with 0.75g BID [twice a day], 1g TID and 1.5g TID regimen, respectively, and one patient with renal hyperfiltration was treated with 2g QID [four times a day] regimen. In all patients, cefiderocol was infused over 3-hours. Concerning the ceftobiprole, all patients were treated with 500mg TID regimen infused over 2-hours. Both analytes were easily detected and measured in patients' plasma. The results are represented in **Figure 3**. Moreover, as shown in **Figure 2A5 and 2B5**, no interferences were observed between ceftobiprole or cefiderocol and endogenous compounds or others drugs given to participating ICU patients.

4. Discussion

We present here a liquid chromatography-isotope dilution tandem mass spectrometry method for the simultaneous measurement of cefiderocol and ceftobiprole. Based on the high recovery, relatively low intra- and inter-day CVs, and good linearity, the present method is suitable for detection and quantification of these two antibiotics in human plasma. To the best of our knowledge, very few analytical methods intended for routine cefiderocol or ceftobiprole clinical application have yet been published. Lima *et al.* reported an HPLC-UV method for measurement of ceftobiprole in human plasma with concentration range of 1-80 mg/L [8]. Likewise, Mernissi *et al.* and Zimmer *et al.* reported an HPLC-UV method for

325 routine therapeutic drug monitoring of cefiderocol with concentration range of 2.5-100 mg/L
326 and 4-160 mg/L, respectively [29, 30]. Although HPLC-UV has the advantage of being cost-
327 effective and easily accessible to most laboratories, HPLC-MS/MS method operating the
328 multiple reaction monitoring has become one the top choices for high speed selective and
329 sensitive analysis of compounds including drugs [31]. HPLC-MS/MS has been employed for
330 cefiderocol and ceftobiprole PK studies in healthy volunteers [18, 32, 33] but in these reports,
331 information about the analytical methods is lacking making their reproducibility difficult. Our
332 method is the first method allowing the simultaneous determination of cefiderocol and
333 ceftobiprole by mass spectrometric detection (analysed using their respective isotopic internal
334 standard) and designed to perform their therapeutic monitoring in a routine setting.

335 The specificity of our method was acceptable since we did not observed interference with
336 endogenous compounds or drugs given to patients hospitalized in ICU. Likewise, the
337 sensitivity was sufficient with a first calibration point (1 mg/L for cefiderocol and 0.5 mg/L
338 for ceftobiprole) well below the mean trough concentration measured in clinical studies and in
339 our patients. This new method uses a wide concentration range which makes it suitable for the
340 measurements of concentration for future pharmacokinetic studies. In comparison to other
341 methods intended for routine clinical application, the current one has an extended lower and
342 upper limit of quantification for both antibiotics. Given the potentially high plasma
343 concentration variability, this could be interesting in case of very low concentration at C_{min}
344 and very high concentration at C_{max} . In addition, compared to the previously reported HPLC-
345 UV methods for which the run times analysis varies from 12-15 min [8, 29, 30], our method is
346 rapid with fast sample preparation and run times (5 min) and requires only a small volume of
347 plasma (100 μ L), which could reduce the time required for quantification of large number of
348 samples and the blood volume collected from the patients.

349 Concerning stability, we found that cefiderocol and ceftobiprole samples should be dispatched

to the laboratory without delay due to their poor stability at room temperature (<24h). This is an important information for the management of the pre-analytical stage and to manage shipping of samples coming from other hospitals. Likewise, both antibiotics were stable for at least 2 months at -80°C in plasma. This is particularly important for clinical research protocols, where samples may need to be stored for a long time before they can be assayed. Our stability results for cefiderocol were consistent with those reported by Mernissi *et al.* [29], but significantly differs from those reported by Zimmer *et al.* [30] in particular for bench-top and fridge stability.

Concerning the clinical application, conducted in critically ill patients, our results suggest that there is significant inter-individual plasma concentration variability; this argues to consider cefiderocol and ceftobiprole as candidates for TDM in this patient population. A PK/PD studies should be performed to explore if this exposure variability can influence their efficacy or toxicity and to define their therapeutic targets concentration.

5. Conclusion

We have developed and validated a rapid, sensitive, selective, accurate, precise and reliable UPLC-MS/MS method for the simultaneous quantification of cefiderocol and ceftobiprole in human plasma. This method was successfully applied to their therapeutic monitoring and will allow us to carry out PK/PD studies in critically ill patients.

Acknowledgments: None.

Research funding: None declared.

Author contributions: **B.L:** Conceptualization, investigation, validation, data analysis, visualization, writing-original draft, writing-review and editing. **A.B:** investigation, writing-review and editing. **D.S:** investigation. **P.R:** investigation. **O.P:** investigation, writing-review and editing. **N.T:** investigation, writing-review and editing. **G.N:** investigation, writing-review and editing. **H.J:** investigation, writing-review and editing. **CE.L:** investigation, writing-review and editing. **C.FB:** investigation, writing-review and editing. **N.Z:** supervision, conceptualization, investigation, writing-review and editing. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: **A.B** has received fees from Shionogi, the manufacturer of cefiderocol. **CE.L** has received grant and travel fees from Correio, the manufacturer of ceftobiprole. Other authors state no conflict of interest.

Informed consent: French regulations on non-interventional observational studies do not require patient's consent when analyzing data obtained from routine care.


Ethical approval: Approval for data collection was obtained from the Commission Nationale de l'Informatique et des Libertés (n°1491960v0).

References


1. Morosini MI, Diez-Aguilar M, Canton R. Mechanisms of action and antimicrobial activity of ceftobiprole. *Rev Esp Quimioter.* 2019;32 Suppl 3:3-10.
2. Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. *Clin Infect Dis.* 2010;51 Suppl 1:S48-53.
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax.* 2012;67(1):71-9.
4. Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. *Clin Infect Dis.* 2014;59(1):51-61.
5. Nicholson SC, Welte T, File TM, Jr., Strauss RS, Michiels B, Kaul P, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. *Int J Antimicrob Agents.* 2012;39(3):240-6.
6. Torres A, Mouton JW, Pea F. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. *Clin Pharmacokinet.* 2016;55(12):1507-20.
7. Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. *Antimicrob Agents Chemother.* 2014;58(5):2512-9.
8. Lima B, Bodeau S, Quinton MC, Leven C, Lemaire-Hurtel AS, Bennis Y. Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole. *Antimicrob Agents Chemother.* 2019;63(7).
9. Andrei S, Droc G, Stefan G. FDA approved antibacterial drugs: 2018-2019. *Discoveries (Craiova).* 2019;7(4):e102.
10. Antibiotic Resistance Threats in the United States, 2019.
<http://dx.doi.org/10.15620/cdc:82532>.
11. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in *Pseudomonas aeruginosa*. *Hippokratia.* 2012;16(4):303-7.
12. Tillotson GS. Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance? *Infect Dis (Auckl).* 2016;9:45-52.
13. Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. *Clin Infect Dis.* 2019;69(Suppl 7):S521-S8.
14. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. *Open Forum Infect Dis.* 2015;2(2):ofv050.
15. Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. *Clin Infect Dis.* 2019;69(Suppl 7):S565-S75.
16. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). *Antimicrob Agents Chemother.* 2017;61(9).
17. Portsmouth S, van Veenhuizen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. *Lancet Infect Dis.* 2018;18(12):1319-28.
18. Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects. *Antimicrob Agents Chemother.* 2018;62(3).
19. Kawaguchi N, Katsube T, Echols R, Wajima T. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis. *Antimicrob Agents Chemother.* 2018;62(2).

20. Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment. *J Clin Pharmacol*. 2017;57(5):584-91.
21. Kawaguchi N, Katsube T, Echols R, Wajima T. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection. *Antimicrob Agents Chemother*. 2021;65(3).
22. Neuner EA, Gallagher JC. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae. *Virulence*. 2017;8(4):440-52.
23. Parker SL, Abdul-Aziz MH, Roberts JA. The role of antibiotic pharmacokinetic studies performed post-licensing. *Int J Antimicrob Agents*. 2020;56(6):106165.
24. Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. *J Antimicrob Chemother*. 2016;71(1):196-207.
25. Scharf C, Liebchen U, Paal M, Taubert M, Vogeser M, Irlbeck M, et al. The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. *J Intensive Care*. 2020;8(1):86.
26. Gatti M, Pea F. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. *Expert Rev Clin Pharmacol*. 2021.
27. Bioanalytical method validation. European Medicines Agency. 2018. <https://www.ema.europa.eu/en/bioanalytical-method-validation>.
28. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. *Anal Chem*. 2003;75(13):3019-30.
29. Mernissi T, Bodeau S, Andre C, Zahr N, Mary A, Dupont H, et al. An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients. *J Antimicrob Chemother*. 2021.
30. Zimmer J, Rohr AC, Kluge S, Faller J, Frey OR, Wichmann D, et al. Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol. *Antibiotics (Basel)*. 2021;10(3).
31. Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. *Clin Biochem Rev*. 2009;30(1):19-34.
32. Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y. Metabolism, Excretion, and Pharmacokinetics of [(14) C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration. *J Clin Pharmacol*. 2019;59(7):958-67.
33. Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. *Antimicrob Agents Chemother*. 2004;48(7):2576-80.


A




Full scan (precursor ion)




Daughter scan (product ion)



B



Full scan (precursor ion)



Daughter scan (product ion)










Figure 1. Chemical structures and mass spectrum of (A) cefiderocol and (B) ceftobiprole

A Cefotibiprole




B Cefiderocol


Q 752.10>285.20 (+) 8.24e3




Q 752.10>285.20 (+) 9.22e6



ISTD 764.10>297.30 (+) 3.37e4



Q 752.10>285.20 (+) 1.64e2



Q 752.10>285.20 (+) 1.01e6




Figure 2. MRM ion-chromatograms of (A1) blank human plasma spiked with ceftobiprole at 0.5 mg/L (LLOQ), (A2) blank human plasma spiked with ceftobiprole at 100 mg/L (ULOQ), (A3) d4-ceftobiprole (IS of ceftobiprole) at 10 mg/L, (A4) blank human plasma without ceftobiprole, (A5) real patient sample treated with ceftobiprole at Ctrough, (B1) blank human plasma spiked with cefiderocol at 1 mg/L (LLOQ), (B2) blank human plasma spiked with cefiderocol at 200 mg/L (ULOQ), (B3) d12-cefiderocol (IS of cefiderocol) at 10 mg/L, (B4) blank human plasma without cefiderocol, (B5) real patient sample treated with cefiderocol at 15min after the end of infusion.







Figure 3. Observed (A) cefiderocol (n = 10) and (B) ceftobiprol (n = 25) plasma concentration at steady-state Ctrough (the median time of blood collection was 2 [1-5] days after start treatment) and at Cmax (samples were collected at 15 ± 10 min after the end of infusion). The box plot show the interquartile and extreme range, the mean (+) and median (horizontal line) values for each group.

A. [2H₁₂]-cefiderocol



B. [2H₄]-ceftobiprole



Supplementary Figure 1. Mass spectrum of (A) [2H₁₂]-cefiderocol and (B) [2H₄]-ceftobiprole

Table 1. Analyte quantification characteristics

Analyte	Retention Time (min)	Precursor (m/z)	Product (m/z)	Dwell Time (msec)	Q1 Pre Bias (V)	CE (V)	Q3 Pre Bias (V)
Cefiderocol	2,69	752,10	285,20 (Quantifier ion)	1,0	-34,0	-20,0	-18,0
		752,10	214,20 (Qualifier ion)	1,0	-34,0	-52,0	-21,0
Ceftobiprol	0,46	535,00	203,30 (Quantifier ion)	1,6	-24,0	-31,0	-19,0
		535,00	69,10 (Qualifier ion)	1,6	-24,0	-32,0	-27,0
[2H ₁₂]-Cefiderocol	2,69	764,10	297,30	1,0	-36,0	-21,0	-19,0
[2H ₄]-Ceftobiprol	0,46	539,30	207,30	1,6	-24,0	-31,0	-20,0

CE: collision energy

Table 2. Summarized results of the precision and accuracy experiments.

QC levels	NC (mg/L)	Intra-day				Inter-day			
		n	Mean measured concentration (mg/L)	CV (%)	Accuracy (%)	n	Mean measured concentration (mg/L)	CV (%)	Accuracy (%)
Cefiderocol									
LLOQ	1	6	1,18	7,8	118	18	1,15	14,7	115
LQC	2,5	6	2,62	5,3	105	18	2,38	7,2	95
MQC	25	6	22,8	3,3	91	18	23,3	7,1	92
HQC	160	6	173	2,6	108	18	163	4,5	102
Ceftobiprol									
LLOQ	0,5	6	0,58	12,5	116	18	0,54	15,2	108
LQC	1	6	0,95	4,7	95	18	0,97	10,2	97
MQC	10	6	9,4	4,2	94	18	9,9	7,7	99
HQC	80	6	77,5	3,6	97	18	79,2	6,4	99

NC: nominal concentration, n: number of replicate, CV: coefficient of variation

Table 3. Absolute matrix effect (ME), IS-normalized ME and absolute extraction recovery (ER) at low and high concentration with their corresponding CVs (n = 5).

Analyte	Low concentration			High concentration		
	ME% (CV%)	IS-normalized ME% (CV%)	ER% (CV%)	ME% (CV%)	IS-normalized ME% (CV%)	ER% (CV%)
Cefiderocol	145 (4,6)	105 (7,0)	90 (9,6)	178 (7,6)	104 (9,2)	99 (6,1)
Ceftobiprol	102 (4,1)	107 (6,5)	93 (6,0)	96 (1,4)	102 (2,8)	103 (8,2)

n: number of replicates

Table 4. Stability under different storage conditions (n = 3).

Storage condition	Cefiderocol			Ceftobiprol		
	Nominal Concentration (mg/L)	Mean Measured (mg/L) (CV%)	Accuracy (%)	Nominal Concentration (mg/L)	Mean Measured (mg/L) (CV%)	Accuracy (%)
Bench-top stability: 25°C up to 8h						
LQC	2,5	2,25 (11,7)	90	1	0,89 (8,7)	89
MQC	25	21,5 (4,5)	86	10	9,5 (5,4)	95
HQC	160	160 (2,6)	100	80	72,2 (5,7)	90
Fridge stability: 4-8°C up to 24h						
LQC	2,5	2,28 (4,3)	91	1	1,12 (8,4)	110
MQC	25	25,5 (3,5)	102	10	9,8 (6,2)	98
HQC	160	155 (3,0)	97	80	73,6 (3,6)	92
Autosampler extract stability: 8°C up to 24h						
LQC	2,5	2,43 (4,5)	97	1	1,05 (13,3)	105
MQC	25	25,3 (8,3)	101	10	9,9 (3,0)	99
HQC	160	170 (6,5)	106	80	73,6 (7,3)	92
Freeze-thaw stability: 3 cycles of -80°C to 25°C						
LQC	2,5	2,55 (12,2)	102	1	1,04 (12,5)	104
MQC	25	23,5 (3,4)	94	10	10,0 (9,0)	100
HQC	160	157 (5,7)	98	80	77,6 (5,1)	97
Freezer stability: -25°C up to 1 week						
LQC	2,5	2,2 (4,8)	89	1	1,14 (13,6)	111
MQC	25	24,3 (3,9)	97	10	10,9 (3,6)	109
HQC	160	150 (1,9)	94	80	72,2 (3,2)	90
Long term stability: -80°C up to 2 months						
LQC	2,5	2,23 (1,2)	89	1	0,95 (7,0)	95
MQC	25	25,1 (1,8)	100	10	9,9 (1,5)	99
HQC	160	157 (3,3)	98	80	83,2 (7,1)	104

n: number of replicates